MSMona Saheli

Mona Saheli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mona Saheli has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial

    by Masoumeh Baghalishahi, Maysam Yousefi, Seyed Noureddin Nematollahi-Mahani, Mahsa Ziasistani, Fahimeh Pourjafari, Mona Saheli

    Background: Previous investigations have indicated the potential of mesenchymal stem cell (MSC) transplantation in treating COVID-19. However, the limited lifespan of transplanted cells constrains this therapeutic approach. the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs secretome could be a promising solution to improve patient outcomes. Materials and Methods: A randomized clinical trial was conducted in Kerman, a region in south-central Iran. This study enrolled twenty patients in the severe phase of COVID-19 pneumonia, randomly allocated into either investigation or control groups. Both groups received standard therapy, the investigation group additionally received nebulized concentrated MSCs secretome, 2 mL administered twice daily for five consecutive days. To evaluate the effect of MSCs secretome therapy, the length of stay in the intensive care unit (ICU), oximetry, and paraclinical results were assessed at baseline and 5 days after ICU admission. Results: Baseline characteristics were balanced and distributed among the two groups. No adverse effect was observed in MSCs secretome-treated patients. Compared to the control group, the investigated group exhibited a decrease in ICU stay duration (10.90 ± 3.75 vs. 5.50 ± 1.64 days, P = 0.04) and a significant improvement in O2 saturation (60.65 ± 16.58 vs. 79.47 ± 15.36, P = 0.02). In addition, significant decreases in CRP, PTT, and INR and upregulation in lymphocyte fraction were observed in the investigation group during the study period. Conclusions: The findings of this study underscore the prospective advantages and safety of the secretome of MSCs as a viable therapeutic choice in COVID-19 patients. We advise verifying our results through additional clinical trials at various disease stages.


  • Open Access

    Athletes’ Mesenchymal Stem Cells Could Be the Best Choice for Cell Therapy in Omicron-Infected Patients

    by Mona Saheli, Kayvan Khoramipour, Massoud Vosough, Abbas Piryaei, Masoud Rahmati, Katsuhiko Suzuki

    New severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, Omicron, contains 32 mutations that have caused a high incidence of breakthrough infections or re-infections. These mutations have reduced vaccine protection against Omicron and other new emerging variants. This highlights the need to find effective treatment, which is suggested to be stem cell-based therapy. Stem cells could support respiratory epithelial cells and they could restore alveolar bioenergetics. In addition, they can increase the secretion of immunomodulatory cytokines. However, after transplantation, cell survival and growth rate are low because of an inappropriate microenvironment, and stem cells face ischemia, inflammation, and oxidative stress in the transplantation niche which reduces the cells’ survival and growth. Exercise-training can upregulate antioxidant, anti-inflammatory, and anti-apoptotic defense mechanisms and increase growth signaling, thereby improving transplanted cells’ survival and growth. Hence, using athletes’ stem cells may increase stem-cell therapy outcomes in Omicron-affected patients.